JP7570925B2 - インビボ受容体占有率を決定するためのアッセイ - Google Patents

インビボ受容体占有率を決定するためのアッセイ Download PDF

Info

Publication number
JP7570925B2
JP7570925B2 JP2020563439A JP2020563439A JP7570925B2 JP 7570925 B2 JP7570925 B2 JP 7570925B2 JP 2020563439 A JP2020563439 A JP 2020563439A JP 2020563439 A JP2020563439 A JP 2020563439A JP 7570925 B2 JP7570925 B2 JP 7570925B2
Authority
JP
Japan
Prior art keywords
btk
drug
bound
quencher
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020563439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523367A (ja
JPWO2019217684A5 (enExample
Inventor
ナイユ・ジェン
イアン・マッコーリー・キャトレット
ジアニン・ゼン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2021523367A publication Critical patent/JP2021523367A/ja
Publication of JPWO2019217684A5 publication Critical patent/JPWO2019217684A5/ja
Priority to JP2024177293A priority Critical patent/JP2025011208A/ja
Application granted granted Critical
Publication of JP7570925B2 publication Critical patent/JP7570925B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2020563439A 2018-05-10 2019-05-09 インビボ受容体占有率を決定するためのアッセイ Active JP7570925B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024177293A JP2025011208A (ja) 2018-05-10 2024-10-09 インビボ受容体占有率を決定するためのアッセイ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669442P 2018-05-10 2018-05-10
US62/669,442 2018-05-10
PCT/US2019/031524 WO2019217684A1 (en) 2018-05-10 2019-05-09 Assay to determine in vivo receptor occupancy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024177293A Division JP2025011208A (ja) 2018-05-10 2024-10-09 インビボ受容体占有率を決定するためのアッセイ

Publications (3)

Publication Number Publication Date
JP2021523367A JP2021523367A (ja) 2021-09-02
JPWO2019217684A5 JPWO2019217684A5 (enExample) 2022-04-22
JP7570925B2 true JP7570925B2 (ja) 2024-10-22

Family

ID=66821369

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020563439A Active JP7570925B2 (ja) 2018-05-10 2019-05-09 インビボ受容体占有率を決定するためのアッセイ
JP2024177293A Withdrawn JP2025011208A (ja) 2018-05-10 2024-10-09 インビボ受容体占有率を決定するためのアッセイ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024177293A Withdrawn JP2025011208A (ja) 2018-05-10 2024-10-09 インビボ受容体占有率を決定するためのアッセイ

Country Status (7)

Country Link
US (2) US12085564B2 (enExample)
EP (1) EP3791183B1 (enExample)
JP (2) JP7570925B2 (enExample)
KR (2) KR20250021652A (enExample)
CN (2) CN112105930B (enExample)
ES (1) ES2992942T3 (enExample)
WO (1) WO2019217684A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3791183B1 (en) 2018-05-10 2024-07-24 Bristol-Myers Squibb Company Assay to determine in vivo receptor occupancy
CN115932261B (zh) * 2022-08-15 2025-07-25 广州医科大学附属第五医院 一种btk受体占有率的检测方法
CN116482345B (zh) * 2023-06-16 2023-09-22 军科正源（北京）药物研究有限责任公司 用于检测双靶点药物受体占有率的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012010240A1 (en) 2010-07-19 2012-01-26 Cellzome Ag In vivo method for the evaluation of a compound-target interaction
US20160252509A1 (en) 2013-08-13 2016-09-01 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062255A1 (en) 2007-08-17 2009-03-05 Thallion Pharmaceuticals Inc. Tumor-targeting evaluation methodology and compounds related thereto
WO2016100593A1 (en) * 2014-12-17 2016-06-23 Pharmacyclics Llc Methods and assays for quantification and normalization of kinase and ligand binding
EP3791183B1 (en) 2018-05-10 2024-07-24 Bristol-Myers Squibb Company Assay to determine in vivo receptor occupancy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012010240A1 (en) 2010-07-19 2012-01-26 Cellzome Ag In vivo method for the evaluation of a compound-target interaction
US20160252509A1 (en) 2013-08-13 2016-09-01 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cynthia D. Jesudason, Ph.D，In Vivo Receptor Occupancy in Rodents by LC-MS/MS，Assay Guidance Manual，2017年，https://www.ncbi.nlm.nih.gov/sites/books/NBK424998/

Also Published As

Publication number Publication date
CN112105930A (zh) 2020-12-18
CN113804873B (zh) 2024-06-18
JP2021523367A (ja) 2021-09-02
KR102764357B1 (ko) 2025-02-10
JP2025011208A (ja) 2025-01-23
WO2019217684A1 (en) 2019-11-14
US20210156854A1 (en) 2021-05-27
ES2992942T3 (en) 2024-12-20
US20250085279A1 (en) 2025-03-13
KR20210008028A (ko) 2021-01-20
US12085564B2 (en) 2024-09-10
CN112105930B (zh) 2025-02-28
EP3791183A1 (en) 2021-03-17
CN113804873A (zh) 2021-12-17
EP3791183B1 (en) 2024-07-24
KR20250021652A (ko) 2025-02-13

Similar Documents

Publication Publication Date Title
JP2025011208A (ja) インビボ受容体占有率を決定するためのアッセイ
Kuhn et al. Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma
Faria et al. Comparison of a stable isotope labeled (SIL) peptide and an extended SIL peptide as internal standards to track digestion variability of an unstable signature peptide during quantification of a cancer biomarker, human osteopontin, from plasma using capillary microflow LC–MS/MS
Whiteaker et al. Sequential multiplexed analyte quantification using peptide immunoaffinity enrichment coupled to mass spectrometry
Ocaña et al. An immunoaffinity liquid chromatography–tandem mass spectrometry assay for the quantitation of matrix metalloproteinase 9 in mouse serum
Knight et al. A high-sensitivity electrochemiluminescence-based ELISA for the measurement of the oxidative stress biomarker, 3-nitrotyrosine, in human blood serum and cells
CA2732109A1 (en) Mass spectrometry assay for plasma-renin
Ji et al. A universal strategy for development of a method for absolute quantification of therapeutic monoclonal antibodies in biological matrices using differential dimethyl labeling coupled with ultra performance liquid chromatography-tandem mass spectrometry
Popp et al. An automated assay for the clinical measurement of plasma renin activity by immuno-MALDI (iMALDI)
Zhang et al. Immunoaffinity LC–MS/MS for quantitative determination of a free and total protein target as a target engagement biomarker
US20160238614A1 (en) Process for ultra-sensitive quantification of target analytes in complex biological systems
Zhang et al. LC-MS/MS-based targeted proteomics quantitatively detects the interaction between p53 and MDM2 in breast cancer
Zhao et al. Epitope mapping and targeted quantitation of the cardiac biomarker troponin by SID‐MRM mass spectrometry
Li et al. Peptide and protein quantification using automated immuno-MALDI (iMALDI)
Yang et al. A liquid chromatography–tandem mass spectrometry-based targeted proteomics assay for monitoring P-glycoprotein levels in human breast tissue
Sun et al. Aptamer-based sample purification for mass spectrometric quantification of trastuzumab in human serum
Kim et al. Quantitative analysis of low-abundance serological proteins with peptide affinity-based enrichment and pseudo-multiple reaction monitoring by hybrid quadrupole time-of-flight mass spectrometry
Grote et al. Using pure protein to build a multiple reaction monitoring mass spectrometry assay for targeted detection and quantitation
JP7629278B2 (ja) Ａβペプチドを測定するための抗体セット、Ａβペプチドの測定方法及び試薬キット
Kuhn et al. Multiplexed immunoaffinity enrichment of peptides with anti-peptide antibodies and quantification by stable isotope dilution multiple reaction monitoring mass spectrometry
Zhi et al. Selected reaction monitoring (SRM) mass spectrometry without isotope labeling can be used for rapid protein quantification
Geumann et al. A sandwich enzyme-linked immunosorbent assay for the quantification of insoluble membrane and scaffold proteins
Li et al. A universal SI-traceable isotope dilution mass spectrometry method for protein quantitation in a matrix by tandem mass tag technology
Park et al. Qualification and application of a liquid chromatography–quadrupole time‐of‐flight mass spectrometric method for the determination of trastuzumab in rat plasma
ES3034592T3 (en) Use of lc-ms/ms to quantitate protein biomarkers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240611

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241009

R150 Certificate of patent or registration of utility model

Ref document number: 7570925

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150